SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: AIKIDO PHARMA INC. (Note: Request metadata listed "Dominari Holdings Inc.", but the filing text identifies the registrant as AIKIDO PHARMA INC.)
Filing Date: February 8, 2022
Reporting Period: Event date February 8, 2022; Report signed February 11, 2022.
Context: The Company is a Delaware corporation with common stock (Symbol: AIKI) listed on The Nasdaq Capital Market.
Key Financial Metrics
This Form 8-K is a current report regarding listing status and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Delisting Notice: On February 8, 2022, the Company received written notice from Nasdaq that its common stock failed to regain compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- Compliance History: The Company had previously received a notice on August 10, 2021, and was granted an initial 180-day compliance period ending February 7, 2022.
- Outcome: The stock did not meet the requirement of closing at or above $1.00 per share for 10 consecutive business days during the initial period.
Outlook, Risks, and Management Commentary
- Extended Compliance Period: Nasdaq granted the Company an additional 180-calendar day period to regain compliance, extending until August 8, 2022.
- Risk of Delisting: Failure to meet the minimum bid price requirement by the new deadline could result in the delisting of the Company's common stock from The Nasdaq Capital Market.
- Management Action: The filing confirms the receipt of the notice but does not detail specific strategic actions taken to raise the stock price beyond the requirement to meet the bid price threshold.
Investor Verification Checklist
- Verify the current trading price of AIKI to assess progress toward the $1.00 minimum bid price.
- Monitor subsequent filings for any reverse stock split proposals or other capital structure changes intended to restore compliance.
- Check for any additional correspondence from Nasdaq regarding the August 8, 2022, deadline.
- Confirm the Company's cash position and liquidity status in the most recent 10-K or 10-Q, as this 8-K does not provide financial data.